AU2017337053B2 - Compositions and methods for treating alzheimer's disease and parkinson's disease - Google Patents

Compositions and methods for treating alzheimer's disease and parkinson's disease Download PDF

Info

Publication number
AU2017337053B2
AU2017337053B2 AU2017337053A AU2017337053A AU2017337053B2 AU 2017337053 B2 AU2017337053 B2 AU 2017337053B2 AU 2017337053 A AU2017337053 A AU 2017337053A AU 2017337053 A AU2017337053 A AU 2017337053A AU 2017337053 B2 AU2017337053 B2 AU 2017337053B2
Authority
AU
Australia
Prior art keywords
tablet
syn120
day
another embodiment
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017337053A
Other languages
English (en)
Other versions
AU2017337053A1 (en
Inventor
Thomas R. Malefyt
Christopher G. Salentine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Inc
Original Assignee
Biotie Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Inc filed Critical Biotie Therapies Inc
Publication of AU2017337053A1 publication Critical patent/AU2017337053A1/en
Application granted granted Critical
Publication of AU2017337053B2 publication Critical patent/AU2017337053B2/en
Priority to AU2021277698A priority Critical patent/AU2021277698A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017337053A 2016-09-30 2017-09-29 Compositions and methods for treating alzheimer's disease and parkinson's disease Ceased AU2017337053B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021277698A AU2021277698A1 (en) 2016-09-30 2021-12-01 Compositions and methods for treating Alzheimer's disease and Parkinson's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402357P 2016-09-30 2016-09-30
US62/402,357 2016-09-30
PCT/US2017/054473 WO2018064559A1 (en) 2016-09-30 2017-09-29 Compositions and methods for treating alzheimer's disease and parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021277698A Division AU2021277698A1 (en) 2016-09-30 2021-12-01 Compositions and methods for treating Alzheimer's disease and Parkinson's disease

Publications (2)

Publication Number Publication Date
AU2017337053A1 AU2017337053A1 (en) 2019-04-04
AU2017337053B2 true AU2017337053B2 (en) 2021-09-02

Family

ID=61756894

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017337053A Ceased AU2017337053B2 (en) 2016-09-30 2017-09-29 Compositions and methods for treating alzheimer's disease and parkinson's disease
AU2021277698A Abandoned AU2021277698A1 (en) 2016-09-30 2021-12-01 Compositions and methods for treating Alzheimer's disease and Parkinson's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021277698A Abandoned AU2021277698A1 (en) 2016-09-30 2021-12-01 Compositions and methods for treating Alzheimer's disease and Parkinson's disease

Country Status (10)

Country Link
US (3) US10314798B2 (https=)
EP (1) EP3518914A4 (https=)
JP (1) JP2019529502A (https=)
AR (1) AR109760A1 (https=)
AU (2) AU2017337053B2 (https=)
CA (1) CA3037059A1 (https=)
IL (1) IL265656A (https=)
MX (2) MX387961B (https=)
TW (1) TWI753952B (https=)
WO (1) WO2018064559A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109760A1 (es) 2016-09-30 2019-01-23 Biotie Therapies Inc Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
AU2020377451B2 (en) * 2019-11-04 2025-12-04 Cinclus Pharma Holding AB (publ) Oral formulation of X842

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039132D1 (de) * 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
MX2007007558A (es) * 2004-12-21 2007-07-24 Hoffmann La Roche Derivados de tetralina y de indano y usos de los mismos.
CN101472884A (zh) * 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其用途
FR2974102B1 (fr) * 2011-04-13 2014-08-22 Rhodia Operations Composition polyamide stabilisee
AR109760A1 (es) 2016-09-30 2019-01-23 Biotie Therapies Inc Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Reynir Eyjolfsson, "Design and Manufacture of Pharmaceutical Tablets", Elsevier Science & Technology, 2015, 1-55 *

Also Published As

Publication number Publication date
CA3037059A1 (en) 2018-04-05
US20190142771A1 (en) 2019-05-16
MX2021014093A (es) 2021-12-10
MX2019003720A (es) 2019-09-19
WO2018064559A1 (en) 2018-04-05
US10314798B2 (en) 2019-06-11
JP2019529502A (ja) 2019-10-17
AU2021277698A1 (en) 2021-12-23
EP3518914A4 (en) 2020-06-10
TW201813638A (zh) 2018-04-16
US20180092868A1 (en) 2018-04-05
US20210177783A1 (en) 2021-06-17
AR109760A1 (es) 2019-01-23
EP3518914A1 (en) 2019-08-07
IL265656A (en) 2019-05-30
AU2017337053A1 (en) 2019-04-04
US10973784B2 (en) 2021-04-13
TWI753952B (zh) 2022-02-01
MX387961B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
JP4084309B2 (ja) 単一の結晶形を含有する固形製剤
TWI271193B (en) Pharmaceutical composition comprising 4-(3&#39;-chloro-4&#39;-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof
DK2605757T3 (en) Nalbuphine-based formulations and applications thereof
EP4359076B1 (en) Phenyl pyrrole aminoguanidine salts and formulations
CN112739334B (zh) 结晶丙二酸肾上腺素盐
JP2021500357A (ja) 改善されたブロモクリプチン製剤
CA2936108A1 (en) Novel compositions
AU2021277698A1 (en) Compositions and methods for treating Alzheimer&#39;s disease and Parkinson&#39;s disease
JP2025169294A (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
JP2011507973A (ja) アムロジピンとバルサルタンとの医薬組成物
JP2025527686A (ja) オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物
JP2010530890A (ja) アタザナビルを含む錠剤組成物
WO2019230937A1 (ja) 溶出性に優れた経口固形製剤
JP7336528B2 (ja) ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
EP1781292B1 (en) Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one
US20160317662A1 (en) Stable oral pharmaceutical composition
JP2011153135A (ja) タルチレリン製剤およびタルチレリン製剤の溶出性維持方法
CN102088961A (zh) 依普罗沙坦组合物
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
WO2007030589A2 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
KR101584919B1 (ko) 암로디핀 경구 붕해형 정제용 조성물 및 이의 제조방법
JP2023551597A (ja) フタラジノン誘導体を含む薬剤学的組成物
CN115105478A (zh) 一种拉考沙胺药物组合物、其制备方法及应用
KR20130033535A (ko) 항-당뇨병제를 함유하는 위-체류형 서방성 정제
HK40045152A (en) Crystalline epinephrine malonate salt

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired